Want to see AU:XEN full AI Analyst Report?
Top Page
AuMake Ltd.
(Sydney:XEN)
Select Model
Select Model
Rating:41Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Upgraded
Date:09/06/26
The score is driven primarily by weak financial performance: sharp FY2026 revenue deterioration, persistent losses (including a gross loss), ongoing negative operating/free cash flow, and materially higher leverage as equity fell. Valuation provides limited support due to negative earnings and no stated dividend yield, while technical analysis is neutral because key indicators were not provided.
Positive Factors
Prior-year revenue expansion
Strong revenue growth in FY2025 demonstrates that the company has previously been capable of expanding sales, indicating some underlying market demand or execution potential. However, the benefit is tempered by the subsequent FY2026 reversal, so this remains an unproven foundation rather than a stable trend.
Negative Factors
Sharp revenue deterioration
A roughly 40% year-over-year revenue decline is a major setback to scale, market position, and operating leverage. Such contraction reduces the revenue base available to cover fixed costs and makes a near-term return to sustainable profitability more difficult, especially after the prior year's growth proved reversible.
Read all positive and negative factors
Positive Factors
Negative Factors
Prior-year revenue expansion
Strong revenue growth in FY2025 demonstrates that the company has previously been capable of expanding sales, indicating some underlying market demand or execution potential. However, the benefit is tempered by the subsequent FY2026 reversal, so this remains an unproven foundation rather than a stable trend.
Read all positive factors
AuMake Ltd. (XEN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.62M
Dividend Yield0.01%
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-0.31
Revenue Growth-49.44%
EPS Growth7.14%
CountryAU
EmployeesN/A
SectorConsumer Cyclical
Sector Strength84
IndustryDepartment Stores
Share Statistics
EPS (TTM)<0.01
Shares Outstanding4,538,525,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)27.83
Price to Sales (P/S)0.35
P/FCF Ratio-6.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
AuMake Ltd. Business Overview & Revenue Model
Company Description
Xenitra Limited operates an e-commerce platform, facilitating the online sale of a broad spectrum of products throughout Australia, Hong Kong, Mainland China, and New Zealand. Its extensive inventory features a wide selection of beverages, both al...
How the Company Makes Money
null...
AuMake Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
28
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.11M | 39.77M | 25.87M | 2.67M | 6.01M |
| Gross Profit | -2.25M | 968.93K | 843.62K | 60.17K | -3.61M |
| EBITDA | -5.47M | -3.39M | -5.85M | -2.11M | -4.78M |
| Net Income | -5.18M | -3.48M | -6.28M | -3.03M | -6.07M |
Balance Sheet | |||||
| Total Assets | 4.44M | 8.30M | 4.37M | 6.37M | 10.08M |
| Cash, Cash Equivalents and Short-Term Investments | 3.16M | 1.72M | 2.03M | 1.55M | 3.04M |
| Total Debt | 1.21M | 1.16M | 2.19M | 0.00 | 520.24K |
| Total Liabilities | 4.26M | 5.64M | 3.80M | 1.26M | 5.98M |
| Stockholders Equity | 252.00K | 2.55M | 524.74K | 5.11M | 4.18M |
Cash Flow | |||||
| Free Cash Flow | -1.14M | -4.26M | -2.84M | -3.46M | -5.35M |
| Operating Cash Flow | -1.13M | -4.26M | -2.66M | -3.46M | -4.64M |
| Investing Cash Flow | 0.00 | -38.83K | -318.20K | -192.52K | 589.87K |
| Financing Cash Flow | 2.58M | 3.93M | 3.58M | 2.00M | 2.59M |
AuMake Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | AU$322.30M | 29.90 | 23.74% | 4.38% | 4.64% | ― | |
62 Neutral | AU$47.95M | 8.98 | 14.55% | 7.67% | 8.43% | 23.06% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
55 Neutral | AU$245.60M | -6.32 | -19.53% | 8.65% | 3.83% | -251.57% | |
51 Neutral | AU$564.09M | 135.57 | 3.54% | ― | 10.63% | -62.61% | |
45 Neutral | AU$354.19M | -1.16 | -22.14% | 7.69% | 30.31% | -737.99% | |
41 Neutral | AU$13.62M | -2.48 | -549.71% | 0.01% | -49.44% | 7.14% |
* Consumer Cyclical Sector Average
AU:XEN
AuMake Ltd.
―
―
―
AU:KGN
Kogan.com
3.34
-0.42
-11.22%
AU:TPW
Temple & Webster Group Ltd
4.75
-18.18
-79.28%
AU:ADH
Adairs Ltd.
1.31
-1.08
-45.19%
AU:MYR
Myer Holdings Limited
0.20
-0.43
-68.80%
AU:DSK
Dusk Group Ltd.
0.73
-0.06
-7.24%
AuMake Ltd. Corporate Events
Xenitra Confirms Compliance on New Share Issue Under Corporations Act
Sep 1, 2026
Xenitra Limited has issued fully paid ordinary shares without a prospectus, relying on provisions that allow certain share issues without formal disclosure under the Corporations Act. The company has confirmed to investors that it remains complian...
Xenitra Seeks ASX Quotation for 259 Million New Shares
Sep 1, 2026
Xenitra Limited has applied to the Australian Securities Exchange for quotation of 259,000,002 ordinary fully paid shares, with an issue date of 1 September 2026. The new quotation will expand the company’s listed share base, potentially enh...
Xenitra Files Updated Corporate Governance Statement and Appendix 4G with ASX
Aug 31, 2026
Xenitra Limited has lodged its corporate governance statement and a completed Appendix 4G with the ASX for the year ended 30 June 2026, confirming compliance with Listing Rules 4.10.3 and 4.7.3. The statement, approved by the board as at 31 August...
Xenitra Revenue Halves as Annual Loss Deepens and NTA Slides
Aug 31, 2026
Xenitra Limited reported a sharp deterioration in its financial results for the year ended 30 June 2026, with revenue from ordinary activities falling 49.4% to $20.1 million and the net loss attributable to owners widening 48.9% to $5.2 million. T...
Xenitra Plans Major Share and Option Issue on ASX
Aug 24, 2026
Xenitra Limited has notified the ASX of a proposed securities issue comprising up to 515,000,000 ordinary fully paid shares and 280,000,000 options exercisable at $0.004 and expiring in April 2028. The issue, structured as a placement or other typ...
Xenitra Raises A$1.5m to Drive High-Margin Healthcare and Digital Commerce Growth
Aug 24, 2026
Xenitra Limited has raised A$1.5 million via a placement of 500 million new shares at A$0.003 to sophisticated and professional investors, with free-attaching options subject to shareholder approval. The capital will be used as working capital to ...
Xenitra Seeks ASX Trading Halt Ahead of Material Capital Raising
Aug 20, 2026
Xenitra Limited, an ASX-listed company, participates in Australia’s capital markets as a publicly traded entity. Its operations and investor relations are governed by ASX listing rules and compliance requirements, which shape how material co...
Xenitra expands into specialised medical nutrition with A$5m FSMP deal
Aug 17, 2026
Xenitra’s Hong Kong-based subsidiary Fukang has signed a three-year framework purchase agreement with Joy Charm Limited to supply Food for Special Medical Purposes products, targeting aggregate procurement of A$5 million. The deal extends Xe...
Xenitra outlines investor information and broad risk warnings
Jul 30, 2026
Xenitra Limited has issued an investor presentation outlining general information on its current activities and reiterating that the document is for information purposes only, not a prospectus or formal offer of securities. The company emphasises ...
Xenitra Delivers Cash-Flow Turnaround as OPAL and OTC Strategies Take Hold
Jul 29, 2026
Xenitra Limited, an Australian health products company listed on the ASX, is reshaping its business around three pillars: nutritionals, over-the-counter medicines and OPAL-tokenised sales. The firm is reducing exposure to low-margin, working-capit...
Xenitra Secures $12m OTC Deal to Drive China Healthcare Push
Jul 26, 2026
Xenitra Limited has signed a three-year pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading, one of China’s leading omnichannel distributors across e-commerce platforms and retail pharmacies. The deal, execute...
Xenitra Schedules Investor Webinar to Highlight Asian Growth Strategy
Jun 9, 2026
Xenitra Limited has invited investors and shareholders to participate in an online webinar scheduled for 1:30 p.m. on Thursday, 11 June, signalling an effort to deepen engagement with the market. The session is expected to provide investors with i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.